Gyre Therapeutics (GYRE) Accumulated Expenses (2010 - 2026)

Gyre Therapeutics (GYRE) has 17 years of Accumulated Expenses data on file, last reported at $15.4 million in Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $15.4 million, down 10.58% year-over-year; the trailing twelve-month figure through Mar 2026 was $15.4 million (down 10.58% YoY), and the FY2025 annual result was $14.4 million, up 35.27% from the prior year.
• Accumulated Expenses improved to $15.4 million in Q1 2026 per GYRE's latest filing, from $14.4 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $17.2 million in Q1 2025 and troughed at $708000.0 in Q3 2023.
• A 5-year average of $8.4 million and a median of $10.5 million in 2024 frame the typical range for Accumulated Expenses.
• On a YoY basis, Accumulated Expenses climbed as much as 5046.67% in 2022 and fell as far as 63.79% in 2022.
• A 5-year view of Accumulated Expenses shows it stood at $9.3 million in 2022, then climbed by 28.83% to $11.9 million in 2023, then dropped by 11.06% to $10.6 million in 2024, then soared by 35.27% to $14.4 million in 2025, then advanced by 7.35% to $15.4 million in 2026.
• Business Quant data shows GYRE's Accumulated Expenses at $15.4 million in Q1 2026, $14.4 million in Q4 2025, and $11.8 million in Q3 2025.